What emerging trends in the FDA’s most coveted designations might tell us
Marked shifts in the pursuit and grant of high-order designations raise fascinating questions. What factors might be driving the sharp downturns in CDER breakthrough designations? And does the sharp post-pandemic upturn in high-order designations by CBER represent a shifting of enthusiasm in favor of advanced therapies? This report, analyzing recent data from the FDA, gives critical insights into market shifts in high-order designations and what it might mean for drug developers.
Related Insights
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Related Insights
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021